1519270968350367744

We presented Phase 3 data on our lead advanced cell therapy candidate, omidubicel, and its advantages of early engraftment and lower infections compared to umbilical cord blood transplantation. Learn more here: https://t.co/uFlZkXEl8p

#Tandem22 https://t.co/KEUvHnyX6x

Send us a message